A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Glioblastoma MultiformeBrain Neoplasms
Interventions
DRUG

OncoGel (ReGel/Paclitaxel)

OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.

Trial Locations (5)

14642

University of Rochester Medical Center, Rochester

21231

The Johns Hopkins University, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

37212

Vanderbilt University Medical Center, Nashville

60637

The University of Chicago Brain Tumor Center, Chicago

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY